These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36521352)

  • 1. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
    Colomba E; Alexandre J; Le Teuff G; Genestie C; Coupez D; Coquard IR; Brachet PE; de Percin S; Sajous C; Fabbro M; Delanoy N; Joly F; Frenel JS; Pautier P; Leary A
    Gynecol Oncol; 2023 Feb; 169():78-84. PubMed ID: 36521352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
    Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
    Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
    Smyth EC; Wotherspoon A; Peckitt C; Gonzalez D; Hulkki-Wilson S; Eltahir Z; Fassan M; Rugge M; Valeri N; Okines A; Hewish M; Allum W; Stenning S; Nankivell M; Langley R; Cunningham D
    JAMA Oncol; 2017 Sep; 3(9):1197-1203. PubMed ID: 28241187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.
    Bernard L; How JA; Patel S; Yates MS; Jazaeri A
    Gynecol Oncol; 2024 Jan; 180():139-145. PubMed ID: 38091773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
    Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):717-729. PubMed ID: 38863432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
    Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer.
    Guo J; Tang B; Fu J; Zhu X; Xie W; Wang N; Ding Z; Song Z; Yang Y; Xu G; Xiao X
    Cell Oncol (Dordr); 2024 Apr; 47(2):573-585. PubMed ID: 37847338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
    Tuninetti V; Pace L; Ghisoni E; Quarà V; Arezzo F; Palicelli A; Mandato VD; Geuna E; Cormio G; Biglia N; Borsotti L; Gallo S; Ferrero A; Jacomuzzi E; Fuso L; Pezua Sanjinez JOS; Puppo A; Caglio A; Rognone C; Turinetto M; Scotto G; Di Maio M; Valabrega G
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
    Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
    Oaknin A; Pothuri B; Gilbert L; Sabatier R; Brown J; Ghamande S; Mathews C; O'Malley DM; Kristeleit R; Boni V; Gravina A; Banerjee S; Miller R; Pikiel J; Mirza MR; Dewal N; Antony G; Dong Y; Zografos E; Veneris J; Tinker AV
    Clin Cancer Res; 2023 Nov; 29(22):4564-4574. PubMed ID: 37363992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients.
    Wu Q; Wang Z; Luo Y; Xie X
    BMC Immunol; 2023 Sep; 24(1):27. PubMed ID: 37658314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
    Alouani E; Mercier M; Flecchia C; Auclin E; Hollebecque A; Mazard T; Turpin A; Pernot S; Cohen R; Dutherage M; Kim S; Sclafani F; Ben-Abdelghani M; Herve C; Aparicio T; De La Fouchardière C; Perkins G; Hautefeuille V; Jaffrelot M; Gallois C; Bongard V; Tougeron D; Taïeb J; Guimbaud R
    ESMO Open; 2023 Jun; 8(3):101574. PubMed ID: 37244250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
    Moreau M; Alouani E; Flecchia C; Falcoz A; Gallois C; Auclin E; André T; Cohen R; Hollebecque A; Turpin A; Pernot S; Masson T; Di Fiore F; Dutherge M; Mazard T; Hautefeuille V; Van Laethem JL; De la Fouchardière C; Perkins G; Ben-Abdelghani M; Sclafani F; Aparicio T; Kim S; Vernerey D; Taieb J; Guimbaud R; Tougeron D
    Eur J Cancer; 2024 May; 202():114033. PubMed ID: 38537314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
    Petrelli F; Ghidini M; Ghidini A; Tomasello G
    JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
    Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
    Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dostarlimab for the treatment of advanced endometrial cancer.
    Redondo A; Gallego A; Mendiola M
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors.
    Ziranu P; Pretta A; Pozzari M; Maccioni A; Badiali M; Fanni D; Lai E; Donisi C; Persano M; Gerosa C; Puzzoni M; Bardanzellu F; Ambu R; Pusceddu V; Dubois M; Cerrone G; Migliari M; Murgia S; Spanu D; Pretta G; Aimola V; Balconi F; Murru S; Faa G; Scartozzi M
    Sci Rep; 2023 Mar; 13(1):4397. PubMed ID: 36928082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
    André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
    Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
    Bogani G; Monk BJ; Powell MA; Westin SN; Slomovitz B; Moore KN; Eskander RN; Raspagliesi F; Barretina-Ginesta MP; Colombo N; Mirza MR
    Ann Oncol; 2024 May; 35(5):414-428. PubMed ID: 38431043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.